Heart-focused medical device maker Edwards Lifesciences (EW) reported a Non-GAAP EPS of $0.61 which missed by $0.01, revenue of $1.32B which missed by $10M. EW has revised their guidance for 2022. A number of fundamental analysts have cut their price targets. Not a good morning for EW shareholders this Friday.
More from Investing
Market Holds Its Own Amid the Chaos
Let's check the rotation turning under the surface, the likelihood of rate hikes and why investors are scratching their heads over this action.
UBS Tries to Save the Day, but I Would Withdraw From Buying the Bank
Is UBS Group AG a white knight or something else? Let's check the charts and take a gut check.
Market's Giving Us a Gut-Check, but Not Necessarily a 2000, 2008 Replay
Here's why, despite the unravelling of several major banks, Apple can still be owned and AI is still worth investing in.
How to Trade China's E-commerce PDD Holdings Now
Previously know as Pinduoduo, weak consumer spending has plagued the stock.